LPS/IFN-γ cytotoxicity in oligodendroglial cells: role of nitric oxide and protection by the anti-inflammatory cytokine IL-10

2001 ◽  
Vol 13 (3) ◽  
pp. 493-502 ◽  
Author(s):  
Eduardo Molina-Holgado ◽  
José Miguel Vela ◽  
Angel Arévalo-Martín ◽  
Carmen Guaza
2008 ◽  
Vol 294 (4) ◽  
pp. E709-E718 ◽  
Author(s):  
Klemen Strle ◽  
Robert H. McCusker ◽  
Rodney W. Johnson ◽  
Samantha M. Zunich ◽  
Robert Dantzer ◽  
...  

Prolonged and excessive inflammation is implicated in resistance to the biological actions of IGF-I and contributes to the pathophysiology of neurodegenerative, metabolic, and muscle-wasting disorders. IL-10 is a critical anti-inflammatory cytokine that restrains inflammatory responses in macrophages and T cells by inhibiting cytokine and chemokine synthesis and reducing expression of their receptors. Here we demonstrate that IL-10 plays a protective role in nonhematopoietic cells by suppressing the ability of exogenous IL-1β to inhibit IGF-I-induced myogenin and myosin heavy chain expression in myoblasts. This action of IL-10 is not caused by impairment of IL-1β-induced synthesis of IL-6 or the ability of IL-1β to activate two members of the MAPK family, ERK1/2 and p38. Instead, this newly defined protective role of IL-10 occurs by specific reversal of IL-1β activation of the JNK kinase pathway. IL-10 blocks IL-1β-induced phosphorylation of JNK, but not ERK1/2 or p38, indicating that only the JNK component of the IL-1β-induced MAPK signaling pathway is targeted by IL-10. This conclusion is supported by the finding that a specific JNK inhibitor acts similarly to IL-10 to restore IGF-I-induced myogenin expression, which is suppressed by IL-1β. Collectively, these data demonstrate that IL-10 acts in a novel, nonclassical, protective manner in nonhematopoietic cells to inhibit the IL-1β receptor-induced JNK kinase pathway, resulting in prevention of IGF-I resistance.


2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
Y Zhao ◽  
T Zhang ◽  
X Guo ◽  
C C Wang ◽  
T C Li

Abstract Study question To compare the changing peripheral levels of inflammation-related cytokine profile during a 9-day period after blastocyst transfer between women who did and did not conceive. Summary answer:Successful implantation is associated with transient increase in serum pro-inflammatory cytokine profile followed by a switch to anti-inflammatory cytokine profile prior to confirmation of pregnancy.What is known already: Immunomodulation is thought to be important for the prevention of rejection of the implanting semi-allograft embryo and successful establishment of pregnancy. A successful pregnancy is characterized by a dominance of anti-inflammatory cytokine profile in the peripheral blood in the first and second trimesters of pregnancy. It is achieved by a complex interplay between various immune cells and cytokines at the fetal-maternal interface, among which the key-players are interleukine–10 (IL–10) and transforming growth factor-β1 (TGF-β1). The circulating inflammatory response in the first few days after embryo transfer to the pathophysiology of implantation failure remains unclear. Study design, size, duration: This prospective observational and longitudinal study on 47 women with infertility was performed in an in vitro fertilization unit from December 2018 to August 2019. The amounts of a range of cytokines was measured on serial blood samples obtained during a 9-day period after blastocyst transfer. Participants/materials, setting, methods Serial blood samples were obtained on the day of embryo transfer, and 3, 6, and 9 days afterward for measurement of serum interferon gamma (IFN-γ), tumor necrosis factor alpha, interleukin (IL)–2, IL–4, IL–10, IL–12, IL–13, IL–17, IL–18, and IL–22 using cytometric bead arrays; transforming growth factor beta 1 (TGF-β1) was measured using commercial enzyme-linked immunosorbent assay kits. Main results and the role of chance The cytokine profile was similar between the women who conceived and those who did not on the day of blastocyst transfer. In women who conceived, IFN-γ and IL–17 (pro-inflammatory cytokines) exhibited a transient and significant increase on day 3 after blastocyst transfer, which decreased to the baseline levels by day 6. Meanwhile, IL–10 (anti-inflammatory cytokine) was increased significantly on days 6 and 9, and TGF-β1 (anti-inflammatory cytokine) was increased significantly on day 9 after blastocyst transfer. In women who did not conceive, there was a more pronounced increase in IFN-γ and IL–17 (pro-inflammatory cytokines) on day 3, which was sustained on days 6 and 9 without a switch to an anti-inflammatory cytokine profile. Among women who conceived after blastocyst embryo transfer, there was a transient and modest increase in serum pro-inflammatory cytokine profile (IFN-γ and IL–17) 3 days after blastocyst transfer, which was followed by a switch to anti-inflammatory cytokine profile (increase IL–10 and TGF-β1) by 6 days after blastocyst transfer and the latter increase was sustained 9 days after blastocyst transfer, when pregnancy was confirmed. Limitations, reasons for caution This is an observational study on peripheral blood cytokine levels, so it is not possible to draw conclusions if the implantation failure is due primarily to failure of the embryo to elicit a trigger for the switch or failure of maternal response to a normal trigger released by the embryo. Wider implications of the findings: The characteristic change in peripheral cytokine profile during successful implantation, well before confirmation of pregnancy, may provide an opportunity to develop serum biomarkers to monitor implantation and to understand the mechanism of its failure, especially in women who experience recurrent implantation failure after IVF. Trial registration number Not applicable


2010 ◽  
Vol 31 (4) ◽  
pp. 215-220 ◽  
Author(s):  
Omid Khalilzadeh ◽  
Mehdi Anvari ◽  
Alireza Esteghamati ◽  
Fatemeh Momen-Heravi ◽  
Armin Rashidi ◽  
...  

2020 ◽  
Vol 14 (2) ◽  
pp. 191-199
Author(s):  
Yasuyuki Fujimoto ◽  
Nobuyuki Kuramoto ◽  
Masanori Yoneyama ◽  
Yasu-Taka Azuma

IL-19 is a type of anti-inflammatory cytokine. Since the receptor for IL-19 is common to IL-20 and IL-24, it is important to clarify the role of each of the three cytokines. If three different cytokines bind to the same receptor, these three may have been produced to complement the other two. However, perhaps it is unlikely. Recently, the existence of a novel receptor for IL-19 was suggested. The distinction between the roles of the three cytokines still makes sense. On the other hand, because T cells do not produce IL-19, their role in acquired immunity is limited or indirect. It has been reported that IL-19 causes inflammation in some diseases but does not have an anti-inflammatory effect. In this review, we introduce the current role of IL-19 in each disease. In addition, we will describe the molecular mechanism of IL-19 and its development for the prevention of diseases. IL-19 was previously considered an anti-inflammatory cytokine, but we would like to propose it as an immunoregulatory cytokine.


2012 ◽  
Vol 108 (10) ◽  
pp. 1746-1755 ◽  
Author(s):  
Yu-Yun Gao ◽  
Qing-Mei Xie ◽  
Ling Jin ◽  
Bao-Li Sun ◽  
Jun Ji ◽  
...  

The present study investigated the effects of xanthophylls (containing 40 % of lutein and 60 % of zeaxanthin) on proinflammatory cytokine (IL-1β, IL-6, interferon (IFN)-γ and lipopolysaccharide-induced TNF-α factor (LITAF)) and anti-inflammatory cytokine (IL-4 and IL-10) expression of breeding hens and chicks. In Expt 1, a total of 432 hens were fed diets supplemented with 0 (as the control group), 20 or 40 mg/kg xanthophylls (six replicates per treatment). The liver, duodenum, jejunum and ileum were sampled at 35 d of the trial. The results showed that both levels of xanthophyll addition decreased IL-1β mRNA in the liver and jejunum, IL-6 mRNA in the liver, IFN-γ mRNA in the jejunum and LITAF mRNA in the liver compared to the control group. Expt 2 was a 2 × 2 factorial design. Male chicks hatched from 0 or 40 mg/kg xanthophyll diet of hens were fed a diet containing either 0 or 40 mg/kg xanthophylls. The liver, duodenum, jejunum and ileum were collected at 0, 7, 14 and 21 d after hatching. The results showed thatin ovoxanthophylls decreased proinflammatory cytokine expression (IL-1β, IL-6, IFN-γ and LITAF) in the liver, duodenum, jejunum and ileum and increased anti-inflammatory cytokine expression (IL-4 and IL-10) in the liver, jejunum and ileum mainly at 0–7 d after hatching.In ovoeffects gradually vanished and dietary effects began to work during 1–2 weeks after hatching. Dietary xanthophylls modulated proinflammatory cytokines (IL-1β, IL-6 and IFN-γ) in the liver, duodenum, jejunum and ileum and anti-inflammatory cytokine (IL-10) in the liver and jejunum mainly from 2 weeks onwards. In conclusion, xanthophylls could regulate proinflammatory and anti-inflammatory cytokine expression in different tissues of hens and chicks.


2020 ◽  
Vol 9 (4) ◽  
pp. 184-198 ◽  
Author(s):  
Emily H. Steen ◽  
Xinyi Wang ◽  
Swathi Balaji ◽  
Manish J. Butte ◽  
Paul L. Bollyky ◽  
...  

Hypertension ◽  
2017 ◽  
Vol 70 (suppl_1) ◽  
Author(s):  
Venkateswara R Gogulamudi ◽  
Umadevi Subramanian ◽  
Meaghan Bloodworth ◽  
Kailash N Pandey

Disruption of natriuretic peptide receptor-A (NPRA) gene ( Npr1 ) activates the pro-inflammatory responses, which contributes to the pathogenesis of hypertension and end-organ damage. The objective of this study was to determine the kinetic responses of pro- and anti-inflammatory cytokines in Npr1 gene-knockout (KO) mice. Npr1 0-copy ( Npr1 -/- ), 1-copy ( Npr1 +/- ), and 2-copy ( Npr1 +/+ ) mice were pre-treated with rapamycin and multiplex analyses were done to assess cytokines levels. Pro-inflammatory cytokine, IFN-γ protein levels in plasma and kidney of 0-copy and 1-copy mice were markedly higher compared with 2-copy mice (76±1; 49±2 vs 32±1.3 pg/ml; 79±2; 29±1 vs. 27±0.5 pg/mg, respectively). Similarly, IL-6 levels in plasma and kidney were significantly elevated in 0-copy and 1-copy mice than 2-copy mice (52±1; 27±0.5 vs.12±0.4 pg/ml; 49±1.5; 38±2 vs.18±1.1 pg/mg, respectively). Interestingly, anti-inflammatory cytokine IL-5 protein levels in plasma and kidneys were significantly down-regulated in 0-copy and 1-copy mice than 2-copy mice (6±0.8; 5±0.1 vs. 12±0.5 pg/ml; 6±0.6; 9±0.4 vs. 28±0.5 pg/mg). IL-10 levels in plasma and kidney of 0-copy and 1-copy mice were also significantly decreased than 2-copy mice (22±0.4; 39±1 vs. 62±3 pg/ml; 14±1.7; 36±0.2 vs. 52±3 pg/mg). Rapamycin significantly reduced the levels of IFN- γ in plasma and kidney of 0-copy (50%, 35%) and 1-copy (63%, 55%) mice and IL-6 level in 0-copy (60%, 38%) and in 1-copy (40%, 26%) mice compared with 2-copy mice. In contrast, rapamycin treatment significantly elevated IL-5 levels in plasma and kidneys of 0-copy (68%, 77%) and 1-copy (61%, 64%) mice and IL-10 levels in 0-copy (80%, 78%) and 1-copy (47%, 25%) mice than 2-copy mice. A significant decrease in blood pressure occurred in rapamycin-treated 0-copy (19±4 mmHg) and 1-copy (12±3 mmHg) mice than untreated control mice. The results demonstrate that the expression of pro-inflammatory cytokines is greatly upregulated in Npr1 KO mice compared with 2-copy mice and rapamycin serves as the immune modulator of anti-inflammatory cytokines in these animals. The present findings implicate that rapamycin might act as an anti-inflammatory drug for the treatment of pathophysiology of hypertension-associated inflammation.


2020 ◽  
Vol 79 (4) ◽  
pp. 536-544 ◽  
Author(s):  
Viola Klück ◽  
Rosanne C van Deuren ◽  
Giulio Cavalli ◽  
Amara Shaukat ◽  
Peer Arts ◽  
...  

ObjectiveGout is characterised by severe interleukin (IL)-1-mediated joint inflammation induced by monosodium urate crystals. Since IL-37 is a pivotal anti-inflammatory cytokine suppressing the activity of IL-1, we conducted genetic and functional studies aimed at elucidating the role of IL-37 in the pathogenesis and treatment of gout.MethodsVariant identification was performed by DNA sequencing of all coding bases of IL37 using molecular inversion probe-based resequencing (discovery cohort: gout n=675, controls n=520) and TaqMan genotyping (validation cohort: gout n=2202, controls n=2295). Predictive modelling of the effects of rare variants on protein structure was followed by in vitro experiments evaluating the impact on protein function. Treatment with recombinant IL-37 was evaluated in vitro and in vivo in a mouse model of gout.ResultsWe identified four rare variants in IL37 in six of the discovery gout patients; p.(A144P), p.(G174Dfs*16), p.(C181*) and p.(N182S), whereas none emerged in healthy controls (Fisher’s exact p-value=0.043). All variants clustered in the functional domain of IL-37 in exon 5 (p-value=5.71×10−5). Predictive modelling and functional studies confirmed loss of anti-inflammatory functions and we substantiated the therapeutic potential of recombinant IL-37 in the treatment of gouty inflammation. Furthermore, the carrier status of p.(N182S)(rs752113534) was associated with increased risk (OR=1.81, p-value=0.031) of developing gout in hyperuricaemic individuals of Polynesian ancestry.ConclusionHere, we provide genetic as well as mechanistic evidence for the role of IL-37 in the pathogenesis of gout, and highlight the therapeutic potential of recombinant IL-37 for the treatment of gouty arthritis.


Sign in / Sign up

Export Citation Format

Share Document